Top

Published in:

01-09-2009 | Case Discussion

Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report

Authors: Francesco G. De Rosa, Pierpaolo Terragni, Daniela Pasero, Anna C. Trompeo, Rosario Urbino, Anna Barbui, Giovanni Di Perri, V. Marco Ranieri

Published in: Intensive Care Medicine | Issue 9/2009

Excerpt

Invasive aspergillosis (IA) is increasingly recognized in the intensive care unit (ICU), and new risk factors associated with respiratory colonization or infection by Aspergillus spp. include steroid treatment and chronic lung obstructive disease [1, 2]. In a review of 289 autopsies in the ICU, IA was the leading cause of Goldman class I discrepancy (a missed major diagnosis with major impact on patient management and survival) [3]. …

Meersseman W, Van Wijngaerden E (2007) Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med 33:1679–1681PubMedCrossRef

Bulpa PA, Dive AM, Garrino MG, Delos MA, Gonzalez MR, Evrard PA, Glupczynski Y, Installe EJ (2001) Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 27:59–67PubMedCrossRef

Maris C, Martin B, Creteur J, Remmelink M, Piagnerelli M, Salmon I, Vincent JL, Demetter P (2007) Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch 450:329–333PubMedCrossRef

Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D (2007) Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 10:1–10

Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Resp Crit Care Med 177:27–34PubMedCrossRef

Tasci S, Glasmacher A, Lentini S, Tschubel K, Ewig S, Molitor E, Sauerbruch T, Luderitz B, Rabe C (2006) Pseudomembranous and obstructive Aspergillus tracheobronchitis: optimal diagnostic strategy and outcome. Mycoses 49:37–42PubMedCrossRef

Chang SM, Kuo HT, Lin FJ, Tzen CY, Sheu CY (2005) Pseudomembranous tracheobronchitis caused by Aspergillus in immunocompromized patients. Scand J Infect Dis 37:937–942PubMedCrossRef

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRef

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF (2008) Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 46:327–360PubMedCrossRef

10.

Maertens J, Raad I, Petrikkos G, Borgaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571PubMedCrossRef

11.

Peleg AY, Woods ML (2004) Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrobl Chem 54:803–808CrossRef

12.

Andes D, Safdar N, Marchillo K, Conklin R (2006) Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations liposomal AMB and AMB lipid complex in murine candidiasis models. Antimicrob Ag Chemother 50:674–684CrossRef

13.

Klepser ME, Wolfe EJ, Pfaller MA (1998) Antifungal pharmacidynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother 41:397–401PubMedCrossRef

14.

Sionov E, Mendlovic S, Segal E (2006) Efficacy of amphotericin B or amphotericin-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 53:131–139PubMedCrossRef

15.

Trof RJ, Beishuizen A, bets-Ossenkopp YJ, Girbes ARJ, Groeneveld ABJ (2007) Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 33:1694–1703PubMedCrossRef

Title: Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report
Authors: Francesco G. De Rosa
Pierpaolo Terragni
Daniela Pasero
Anna C. Trompeo
Rosario Urbino
Anna Barbui
Giovanni Di Perri
V. Marco Ranieri
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 9/2009
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-009-1546-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2009

Predictive ability of intra-abdominal pressure for ICU mortality

Intensive care of aneurysmal subarachnoid hemorrhage: an international survey

Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study

Is proportional-assist ventilation with load-adjustable gain factors a user-friendly mode?

Comparison of a new unguided self-advancing jejunal tube with the endoscopic guided technique: a prospective, randomized study

Incidence and risk factors for ventilator-associated pneumonia after major heart surgery